en Radiation Biology Radiation Biology تحقيق بديع Original Research <div style="text-align: justify;"><span style="font-size:10pt"><span style="text-justify:newspaper"><span style="text-kashida-space:50%"><span style="line-height:119%"><span style="font-family:Calibri"><span style="color:black"><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Background</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">To compare the dosimetric parameters, clinical complications, and efficacy of helical tomotherapy (HT) and fixed-field intensity-modulated radiotherapy (f-IMRT) in radical radiotherapy for cervical cancer. </span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Materials and Method</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">From November 2016 to December 2018, 77 cervical cancer patients in radical irradiation were selected, 38 patients undergoing treatment with HT and 39 with f-IMRT. The dosimetic parameters, clinical complications, and efficacy were compared.</span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Results</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">The homogeneity index (HI) and conformity index (CI) of HT plans were both superior to those of f-IMRT plans(</span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="font-style:italic"><span style="language:en-US">P</span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">=0.000). HT plans resulted in a reduction in the dosimetric parameters</span></span></span></span><span lang="en-US" style="font-size:5.9939pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US"></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">of organs at risk (OARs) (</span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="font-style:italic"><span style="language:en-US">P</span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US"><0.05) except the V</span></span></span></span><span lang="en-US" style="font-size:5.9939pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">₁₀</span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">of small intestine (</span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="font-style:italic"><span style="language:en-US">P</span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">=0.682). The incidence of myelosuppression</span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">showed no significant differences (</span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="font-style:italic"><span style="language:en-US">P</span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">=0.265).The patients with HT had no radiocystitis, grade 2 or above radiation proctitis. The complete remission (CR) rates, efficacy rates (CR+PR) and local control rates of two years were 81.58%,100% and 97.37%. </span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Conclusion</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">HT showed advantages in dosimetry, and provided more superior clinical results. It has a good application prospect in radical irradiation for cervical cancer.</span></span></span></span></span></span></span></span></span></span></div> Cervical cancer, dosimetry, helical tomotherapy, intensity-modulated radiotherapy. 377 382 http://ijrr.com/browse.php?a_code=A-10-1-919&slc_lang=en&sid=1 M.F. Guo 7900319475328460021611 7900319475328460021611 No Department of Gynecologic Oncology, Chongqing University Cancer Hospital, Chongqing 400044, China X.J. Zhao 7900319475328460021612 7900319475328460021612 No Department of Gynecologic Oncology, Chongqing University Cancer Hospital, Chongqing 400044, China Y. Huang 7900319475328460021613 7900319475328460021613 No Department of Gynecologic Oncology, Chongqing University Cancer Hospital, Chongqing 400044, China D.K. Chen 7900319475328460021614 7900319475328460021614 No Department of Gynecologic Oncology, Chongqing University Cancer Hospital, Chongqing 400044, China N. Zhang 18908370600@189.cn 7900319475328460021615 7900319475328460021615 Yes Department of Gynecologic Oncology, Chongqing University Cancer Hospital, Chongqing 400044, China